Kovitz Investment Group Partners, LLC Candel Therapeutics, Inc. Transaction History
Kovitz Investment Group Partners, LLC
- $23.6 Billion
- Q3 2025
A detailed history of Kovitz Investment Group Partners, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Kovitz Investment Group Partners, LLC holds 79,316 shares of CADL stock, worth $365,646. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,316Holding current value
$365,646% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
87Shares Held
14.9MCall Options Held
313KPut Options Held
127K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$11.9 Million6.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$9.25 Million0.0% of portfolio
-
Northpond Ventures, LLC1.94MShares$8.92 Million48.35% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.38MShares$6.38 Million0.45% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$4.28 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $133M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...